Sintx Technologies Inc (SINT)
NASDAQ:SINT
Top Page
Sintx Technologies
(NASDAQ:SINT)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.50
▼(-33.16% Downside)
Action:UpgradedDate:03/21/26
The score is driven primarily by very weak financial performance (tiny and contracting revenue, large ongoing losses, and sustained negative free cash flow), which raises financing risk. Technicals are also unfavorable with a broad downtrend, though oversold readings slightly temper the downside. Valuation offers limited support due to negative earnings and no dividend yield provided.
Positive Factors
FDA-cleared product & first clinical case
FDA clearance plus a first-in-human procedure provides durable clinical and regulatory validation of Sintx's silicon nitride implant technology. This milestone materially de-risks entry into the large foot & ankle orthopedic segment and supports longer-term commercialization and adoption opportunities.
Negative Factors
Tiny, declining revenue and large losses
Revenue levels are immaterial relative to operating losses, indicating the company has not achieved scalable commercial traction. Persistent large losses versus tiny revenue make operational self-sufficiency unlikely in the near term and raise structural execution and financing demands.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA-cleared product & first clinical case
FDA clearance plus a first-in-human procedure provides durable clinical and regulatory validation of Sintx's silicon nitride implant technology. This milestone materially de-risks entry into the large foot & ankle orthopedic segment and supports longer-term commercialization and adoption opportunities.
Read all positive factors
Sintx Technologies (SINT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.05M
Dividend YieldN/A
Average Volume (3M)148.79K
Price to Earnings (P/E)―
Beta (1Y)2.30
Revenue Growth-60.89%
EPS Growth94.49%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,121,727
10 Day Avg. Volume107,243
30 Day Avg. Volume148,787
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.66
Price to Sales (P/S)10.52
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue6.94
Enterprise Value/Gross Profit-35.14
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$10.00Price Target Upside167.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sintx Technologies Business Overview & Revenue Model
Company Description
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the ...
How the Company Makes Money
Sintx Technologies generates revenue primarily through commercial and business-to-business arrangements related to its silicon nitride technology. Key revenue streams include: (1) product and technology-related sales connected to silicon nitride c...
Sintx Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.02M | 1.25M | 2.63M | 601.00K | 606.00K |
| Gross Profit | -201.00K | 435.00K | 1.84M | 336.00K | 157.00K |
| EBITDA | -10.06M | -9.61M | -6.60M | -11.06M | -8.63M |
| Net Income | -17.08M | -11.02M | -8.26M | -12.04M | -9.31M |
Balance Sheet | |||||
| Total Assets | 9.51M | 9.41M | 15.37M | 15.77M | 21.84M |
| Cash, Cash Equivalents and Short-Term Investments | 4.14M | 3.60M | 3.34M | 6.25M | 14.27M |
| Total Debt | 3.24M | 4.03M | 4.76M | 3.63M | 2.91M |
| Total Liabilities | 6.58M | 5.52M | 6.59M | 10.07M | 4.64M |
| Stockholders Equity | 2.93M | 3.89M | 8.77M | 5.70M | 17.20M |
Cash Flow | |||||
| Free Cash Flow | -8.76M | -9.33M | -14.64M | -11.67M | -13.87M |
| Operating Cash Flow | -8.57M | -8.64M | -14.12M | -10.26M | -10.13M |
| Investing Cash Flow | 913.00K | -194.00K | -501.00K | -1.10M | -1.66M |
| Financing Cash Flow | 8.20M | 9.09M | 11.71M | 3.34M | 705.00K |
Sintx Technologies Technical Analysis
Neutral
3.74
Price Trends
2.80
Negative
3.23
Negative
3.41
Negative
Market Momentum
-0.06
Negative
50.88
Neutral
75.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SINT, the sentiment is Neutral. The current price of 3.74 is above the 20-day moving average (MA) of 2.58, above the 50-day MA of 2.80, and above the 200-day MA of 3.41, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 50.88 is Neutral, neither overbought nor oversold. The STOCH value of 75.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SINT.
Sintx Technologies Risk Analysis
Sintx Technologies disclosed 42 risk factors in its most recent earnings report. Sintx Technologies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our success will depend on our acquiring revenue generating assets. We may not be successful in acquiring revenue generating assets which will impact our ability fund operations. Q3, 2024
2.
The Company may not be successful in its efforts to transition it focus to advancements in the medical device sector Q3, 2024
3.
The delay in the divesture of our armor, aerospace and defense segments could delay development of our medical device focus resulting in a delay in future revenue. Q3, 2024
Sintx Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $104.01M | -1.56 | 1028.60% | ― | 87.45% | 72.30% | |
44 Neutral | $8.69M | ― | -193.22% | ― | -2.47% | 91.23% | |
43 Neutral | $883.82K | -9.36 | -476.74% | ― | -5.19% | -0.81% | |
43 Neutral | $15.37M | -0.72 | -364.96% | ― | -48.74% | 89.18% | |
43 Neutral | $4.94M | -0.07 | -70.27% | ― | -87.84% | 29.16% | |
42 Neutral | $11.05M | -0.63 | -204.04% | ― | -60.89% | 94.49% |
* Healthcare Sector Average
SINT
Sintx Technologies
2.68
0.83
44.86%
SSKN
Strata Skin Sciences
0.15
-2.37
-94.05%
HSDT
Solana Company
1.89
-222.89
-99.16%
HIND
Vyome Holdings
2.19
-37.33
-94.46%
CODX
Co-Diagnostics
1.37
-9.50
-87.40%
TNON
Tenon Medical, Inc.
0.77
-0.37
-32.54%
Sintx Technologies Corporate Events
Business Operations and StrategyExecutive/Board Changes
Sintx Technologies Appoints Ryan Elmore as New President
Positive
Feb 18, 2026
Effective March 16, 2026, Eric Olson will step down from his role as President of SINTX Technologies, Inc. while retaining his positions as Chairman of the Board and Chief Executive Officer, consolidating his focus on overall corporate strategy an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.